Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Genetic Marker to Help Children with T-Cell Leukemia Avoid Unnecessary Chemotherapy

By LabMedica International staff writers
Posted on 11 Dec 2025

About 400 children in the UK are diagnosed with acute lymphoblastic leukemia (ALL) each year, with roughly 15% presenting with a more aggressive T-ALL subtype. More...

While the standard approach is a four-week course of chemotherapy, approximately 10% of patients show little or no response. However, clinicians currently have no way to predict which cases will resist treatment. This diagnostic gap exposes families to weeks of toxic therapy that may offer little benefit. New research has now identified a previously unrecognized cancer cell type that appears to drive this resistance, opening the door to tests that could prevent unnecessary chemotherapy and guide future targeted therapies.

In a collaborative study involving Cambridge University Hospitals (Cambridge, UK) and the Wellcome Sanger Institute (Hinxton, UK), researchers analyzed single-cell genomes from bone marrow samples of 58 children with T-ALL. They found that some children with T-ALL carry clusters of malignant T-cells that express a protein called ZBTB16. These cells did not respond to first-line chemotherapy and were present at diagnosis, suggesting they could serve as an early biomarker of poor treatment response.

The study, published in Nature Communications, showed that broader genomic analysis across hundreds of T-ALL cases confirmed that ZBTB16 can switch on at various stages of cancer evolution but consistently drives treatment resistance. Since existing diagnostic platforms can already detect ZBTB16, researchers believe the marker could be added to routine testing to identify high-risk patients on the day of diagnosis.

Detecting ZBTB16-positive cells early could help clinicians avoid ineffective treatment and prioritize alternative strategies. The researchers hope that targeting these newly identified resistant cells will eventually yield therapies for T-ALL cases that do not respond to current regimens. In time, this work may help transform care for children with aggressive leukemia, reducing unnecessary toxicity while advancing more effective, biologically informed treatments.

“Being able to identify children who have T-cell leukemia that will not respond to initial treatment on the day of their diagnosis has an immediate impact on their clinical care,” said Dr. David O’Connor, co-senior author. “While further clinical research is needed, the genetic marker we have discovered can also be identified using an already widely used test, meaning that it could be easily adopted into clinical care if proven effective.”

Related Links
Cambridge University Hospitals
Wellcome Sanger Institute


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Graphical Abstract (Matthew A Butzler, Jennifer L Reed, Alaina M Olson, et al. Development of a Rapid Automated Point-of-Care Test for Mycobacterium tuberculosis Detection from Tongue Swabs and Sputum Specimens on the DASH® Rapid PCR System, Open Forum Infectious Diseases, 2026; https://doi.org/10.1093/ofid/ofag706)

Rapid Point-of-Care Test Detects Tuberculosis from Tongue Swab and Sputum

Tuberculosis remains a major infectious disease challenge, particularly in regions with limited access to diagnostic testing and treatment. Diagnosis can be time-consuming, and collecting sputum samples... Read more

Pathology

view channel
Image Credit: Adobe Stock

New Training Approach Helps AI Distinguish Neighboring Cells in Tissue

Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.